Search results for "bronj"

showing 10 items of 11 documents

What happens to the BRONJ patients when re-classified according to the novel SICMF-SIPMO recommendations? Our experience

2014

Background. Since 2009, according to the American Association of Oral and Maxillofacial Surgeons staging system (AAOMS-SS), Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ) has been defined by the presence of bone exposition; in absence of this condition, patients presenting other unspecific clinical and/or radiological signs of disease were classified into the “stage 0”. In 2012, the Italian Society of Maxillo-Facial Surgery (SICMF) and the Italian Society of Oral Pathology and Medicine (SIPMO) redefined BRONJ, as an adverse drug event, with several clinical forms (exposed and not-exposed), and updated the staging system, abolishing the stage 0. Aim of this study was to re-classify …

AbstractsBRONJ
researchProduct

The combination of laser-assisted surgery with PRP for the treatment of BRONJ in cancer patient. A pilot study

2014

Aim. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-known potential complication of bisphosphonates (BPs) therapy and its treatment could reckon on different approaches. Recently, encouraging results for BRONJ were showed from some clinical studies using Er, Cr: YSGG laser-assisted surgery. Platelet-Rich Plasma (PRP), a new approach to promote tissue regeneration and healing, may be a promising complementary therapy. The aim of this pilot study is to study the effectiveness, in terms of clinical healing, of a combined treatment (laserassisted surgery and topical PRP) for BRONJ in a group of cancer patients. Methods. Ten oncological patients (3 males, 7 females; aged 69-89…

AbstractsSettore MED/28 - Malattie OdontostomatologichePRP BRONJ cancerOriginal Article
researchProduct

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Ita…

2011

Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ2 tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most …

AdultMaleCancer Researchmedicine.medical_specialtyTooth extractionmedicine.medical_treatmentZoledronic AcidSettore MED/28 - Malattie OdontostomatologicheRisk FactorsClinical historySpontaneous formmedicineRetrospective analysisHumansStatistical analysisStage (cooking)AgedRetrospective StudiesAged 80 and overSurgical outcomeBone Density Conservation AgentsDiphosphonatesBRONJOrthognathic Surgical Proceduresbusiness.industryImidazolesOsteonecrosisBisphosphonates-related Osteonecrosis of the JawMiddle AgedBisphosphonateSurgeryZoledronic acidItalyOncologyMulticenter studyFemaleBisphosphonate therapyOral SurgerybusinessJaw Diseasesmedicine.drugOral Oncology
researchProduct

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct

Demographic and behavioural profiles of patients with common oral mucosal lesions by a homogeneity analysis

2012

Objective: The aim of this study is to assess the main oral mucosal lesions (OMLs) within a hospital base and to provide an anamnestic, diagnostic model based on homogeneity analysis of some variables. Methods: The demographic and behavioural data (i.e. gender, age, smoking status, alcohol consumption and therapeutic drug usage) of 1753 patients with at least one OML were considered. Multiple correspondence analysis (MCA) and multivariate tests of the simultaneous marginal homogeneity hypothesis (SMH) were used to analyse the evidence of any differences between the demographic and behavioural profiles relating to OMLs diagnoses. Statistical significance of P<0.05 was chosen. Results: With r…

AdultMalesquamous cell carcinomaAdolescentAlcohol DrinkingHealth BehaviorBurning Mouth SyndromeSettore MED/01 - Statistica MedicaYoung AdultSex FactorsDrug TherapySettore MED/28 - Malattie Odontostomatologichemarginal homogeneity hypothesisoral mucosal lesionHumansBMSChildAgedDemographyAged 80 and overhalitosiBRONJSmokingAge FactorsHalitosisMiddle AgedItalyleukoplakiaChild PreschoolCarcinoma Squamous CellBisphosphonate-Associated Osteonecrosis of the JawFemaleMouth NeoplasmsStomatitis AphthousLeukoplakia OralMouth DiseasesRAS
researchProduct

Protocol of BRONJ prevention: successful use of antiseptics during oral surgical procedures

2012

Aim: The overall prevention and treatment of Bisphosphonates related osteonecrosis of the jaws (BRONJ) have been the goals of our project structured (labelled PROMaB) within the hospital AOUP “P. Giaccone” (Italy) in order to make better quality life of patients in therapy with amminobisphosphonates (NBP). Material and Methods: Among all procedures, in case of preprogrammed oral surgical procedure, oral antimicrobial rinses (i.e. chlorexidine 0,2% mouthwash and 0,5% gel, three times/day) plus oral systemic antibiotic therapy –e.g. amoxicilin/clavulanate- have been used to reduce the risk of BRONJ in secondary prevention (1 day before and 6 days after). Three hundred and twenty-one patients …

BRONJ prevention antiseptics oral surgerySettore MED/28 - Malattie Odontostomatologiche
researchProduct

Platelet-rich plasma (PRP) in dental and oral surgery: from the wound healing to bone regeneration

2013

Platelet-rich plasma (PRP) is a new approach to tissue regeneration and it is becoming a valuable adjunct to promote healing in many procedures in dental and oral surgery, especially in aging patients. PRP derives from the centrifugation of the patient's own blood and it contains growth factors that influence wound healing, thereby playing an important role in tissue repairing mechanisms. The use of PRP in surgical practice could have beneficial outcomes, reducing bleeding and enhancing soft tissue healing and bone regeneration. Studies conducted on humans have yielded promising results regarding the application of PRP to many dental and oral surgical procedures (i.e. tooth extractions, per…

PRPAgingmedicine.medical_specialtyPRP Wound healing Bone regeneration Dental surgery Oral surgery Tooth extraction Periodontal surgery Implant surgery BRONJTooth extractionImmunologyWound healingDentistryReviewOral Surgical ProceduresBone tissueImplant surgeryOral surgerySettore MED/28 - Malattie OdontostomatologichemedicinePeriodontal surgeryBone regenerationBRONJbusiness.industrySoft tissuemedicine.diseaseBone regenerationSurgeryAgeingmedicine.anatomical_structureDental surgeryPlatelet-rich plasmaDental surgeryBone maturationOsteonecrosis of the jawbusinessImmunity & Ageing
researchProduct

Proceedings of the Closed Round Table and Italian Consensus on the Medication-Related Osteonecrosis of Jaws (MRONJ) at the Symposium of Italian Socie…

2019

On 20 October 2018 a Closed Round Table brought together a wide range of stakeholders from several medical disciplines, including academic experts, dentists, oncologists, maxillo-facial surgeons, oral surgeons, radiologists, under the technical and scientific coordination of Giuseppina Campisi (for SIPMO) and Giacomo Oteri (for Italian Society of Oral Surgery- SIdCO)

SIPMOBRONJ (bisphosphonate-related osteonecrosis of the jaw)Risk of inappropriatenessSIdCOPhysiologyPhysiology (medical)Italian consensus mrojMRONJ Italian ConsensusMRONJONJ (osteonecrosis of the jaws)BRONJ (bisphosphonate-related osteonecrosis of the jaw)Risk of inappropriatenessMRONJ Italian ConsensusSIPMOSIdCOMRONJONJ (osteonecrosis of the jaws)
researchProduct

The chimeric ALT-vastus lateralis free flap in reconstruction of advanced BRONJ of the maxilla.

2015

Introduction Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a dangerous complication of bisphosphonates, a class of pharmaceutical agents used in numerous bone disor- ders. No gold standard therapy exists, but recent literature suggests that, in advanced stages, the best results are achieved with aggressive debridement. In this paper, we report our experience of treatment of stage 3 BRONJ of the maxilla with extensive surgical debridement and reconstruction with a chimeric ALT-Vastus lateralis flap. Methods Five selected patients with stage 3 BRONJ underwent partial maxillectomy with dis- ease-free margins followed by immediate reconstruction with a chimeric ALT-Vastus lateralis…

Settore MED/19 - Chirurgia Plasticabronj maxilla vastus lateralis flap chimeric flap ALT flap
researchProduct

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with t…

aflibercept; bevacizumab; Bisphosphonate; Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ); denosumab; everolimus; Medication-Related Osteonecrosis of the Jaw (MRONJ); Osteonecrosis of the jaw (ONJ); sunitinib; temsirolimus; Angiogenesis Inhibitors; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Humans; Jaw Diseases; Molecular Targeted Therapy; Neoplasms; Osteonecrosis; Quality of Life; Risk Assessment; Pharmacology (medical)Oncologysunitinibmedicine.medical_treatmentAngiogenesis InhibitorstemsirolimuTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsPharmacology (medical)Molecular Targeted TherapyJaw DiseaseafliberceptOsteonecrosisGeneral MedicineDenosumab030220 oncology & carcinogenesisOsteonecrosiBisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabAntineoplastic AgentsbevacizumabRisk AssessmentBisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)Medication-Related Osteonecrosis of the Jaw (MRONJ)03 medical and health sciencesInternal medicinemedicineBisphosphonateHumansBisphosphonate-associated osteonecrosis of the jawbusiness.industryeverolimuCancerdenosumab030206 dentistryBisphosphonatemedicine.diseaseOsteonecrosis of the jaw (ONJ)Quality of LifeNeoplasmJaw DiseasesOsteonecrosis of the jawbusinessJaw DiseasesExpert Opinion on Drug Safety
researchProduct